Disease-Modifying Therapeutics for Huntington’s Disease: State of the Art

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in HTT. Despite its well-defined genetic cause, developing safe and effective disease-modifying therapies has remained challenging. By September 2026, the therapeutic landscape included regulatory submissions for the adeno-associated virus serotype 5 (AAV5)-delivered RNA interference therapy ifezuntirgene inilparvovec (AMT-130) and the discontinuation of tominersen after the GENERATION HD2 trial, in which target engagement and biomarker responses were achieved without clinical benefit. These contrasting developments highlight both the progress achieved and the challenges of translating molecular interventions into clinical benefit. Here, we review five complementary therapeutic strategies grounded in current understanding of HD pathogenesis: editing the HTT sequence or modifying its epigenetic regulation; suppressing somatic CAG expansion by modulating DNA repair; lowering huntingtin expression with antisense oligonucleotides, AAV-delivered RNA interference and oral splicing modulators; modifying mutant huntingtin aggregation and proteostasis; and targeting downstream pathological processes. Together, these advances support combination approaches targeting multiple pathogenic mechanisms, although their efficacy and safety remain to be established. More than three decades after the identification of the causative mutation, a deeper understanding of HD biology and expanding therapeutic approaches provide grounds for cautious optimism about meaningful improvements for people with HD.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-17
DOI
https://doi.org/10.3390/ijms272210301
Primary Topic
Genetic Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Disease-Modifying Therapeutics for Huntington’s Disease: State of the Art

Stefano Gustincich, Carlotta Bon, Denisa Smělá, Stefano Espinoza et al.
International Journal of Molecular Sciences
Genetic Neurodegenerative Diseases
article

Disease-Modifying Therapeutics for Huntington’s Disease: State of the Art

Stefano Gustincich, Carlotta Bon, Denisa Smělá, Stefano Espinoza, Gloria Ros, Francesca Persichetti, Remo Sanges
article en

Abstract

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in HTT. Despite its well-defined genetic cause, developing safe and effective disease-modifying therapies has remained challenging. By September 2026, the therapeutic landscape included regulatory submissions for the adeno-associated virus serotype 5 (AAV5)-delivered RNA interference therapy ifezuntirgene inilparvovec (AMT-130) and the discontinuation of tominersen after the GENERATION HD2 trial, in which target engagement and biomarker responses were achieved without clinical benefit. These contrasting developments highlight both the progress achieved and the challenges of translating molecular interventions into clinical benefit. Here, we review five complementary therapeutic strategies grounded in current understanding of HD pathogenesis: editing the HTT sequence or modifying its epigenetic regulation; suppressing somatic CAG expansion by modulating DNA repair; lowering huntingtin expression with antisense oligonucleotides, AAV-delivered RNA interference and oral splicing modulators; modifying mutant huntingtin aggregation and proteostasis; and targeting downstream pathological processes. Together, these advances support combination approaches targeting multiple pathogenic mechanisms, although their efficacy and safety remain to be established. More than three decades after the identification of the causative mutation, a deeper understanding of HD biology and expanding therapeutic approaches provide grounds for cautious optimism about meaningful improvements for people with HD.

International Journal of Molecular SciencesVol. 27(22)
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), Scuola Internazionale Superiore di Studi Avanzati (IT), Italian Institute of Technology (IT)
Good health and well-being
Genetic Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon